EUCTR2004-001507-35-HU进行中（未招募）不适用
A Multicenter, Randomized, Open-Label, Parallel-Group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 354
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Have an IPSS score of INT-2 or High and a diagnosis of RAEB or RAEBT per FAB classification criteria or a diagnosis of Myelodysplastic CMMoL per modified FAB criteria meeting the following:
- •a. Monocytosis in peripheral blood >1x109/L,
- •b. Dysplasia in one or more myeloid cell lines,
- •c. 10 to 29% blasts in the BM
- •d. WBC <13,000 X109/L ;
- •2. Be =18 years of age;
- •3. Have a life expectancy =3 months;
- •4. Be unlikely to proceed to bone marrow or stem cell transplantation therapy following remission;
- •5. Be capable of giving informed consent and have signed the informed consent form (ICF);
- •6. Have an Eastern Cooperative Oncology Group (ECOG) Performance Status Grade of 0-2;
- •7. Have serum bilirubin levels =1.5 x the upper limit of the normal range for the laboratory (ULN). Higher levels are acceptable if these can be attributed to active hemolysis (as indicated by positive direct Coombs’ testing, decreased haptoglobin level, elevated indirect bilirubin and/or lactate dehydrogenase [LDH]), or ineffective erythropoiesis (as indicated by bone marrow findings);
- •8. Have serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) levels =2 x ULN;
- •9. Have serum creatinine levels =1.5 x ULN;
- •10. Women of childbearing potential may participate, providing they meet the following conditions:
- •a. Must agree to use at least 2 effective contraceptive methods throughout the
- •study and for 3 months following the date of the last dose of study medication.
- •b. Must have a negative serum pregnancy test obtained within 24 hours prior to Day 1.
- •11. Males with female partner of childbearing potential must agree to use at least 2 effective contraceptive methods throughout the study and should avoid fathering a child for 6 months following the date of the last dose of study medication.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Secondary MDS, i.e., MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation for other diseases;
- •2. Any prior treatment with azacitidine;
- •3. Any prior history of AML;
- •4. Any diagnosis of malignant disease within the previous 12 months (excluding basal cell carcinoma with no complications);
- •5. Any diagnosis of metastatic disease;
- •6. Have hepatic tumors;
- •7. Radiation therapy, chemotherapy, or cytotoxic therapy, given to treat conditions other than MDS and administered within the previous 12 months prior to the first day of treatment (Day 1);
- •8. Known or suspected hypersensitivity to azacitidine or mannitol;
- •9. Prior or active disease that, in the opinion of the Investigator, may interfere with the procedures or evaluations to be conducted in the study;
- •10. Prior transplantation or cytotoxic therapy, including azacitidine and chemotherapy, administered to treat MDS;
- •11. Serious medical illness likely to limit survival to =12 months after screening or likely to prevent granting of informed consent (e.g., history of severe congestive heart failure, clinically unstable cardiac disease, or pulmonary disease);
- •12. Psychiatric illness that would prevent granting of informed consent;
- •13. Treatment with erythropoietin or myeloid growth factors (granulocyte colony-stimulating factor [G-CSF] or granulocyte-macrophage colony-stimulating factor [GM-CSF]) during the previous 21 days prior to Day 1;
- •14. Treatment with androgenic hormones during the previous 14 days prior to Day 1;
- •15. Active viral infection with known human immunodeficiency virus (HIV) or viral hepatitis type B or C;
- •16. Treatment with other investigational drugs within the previous 30 days prior to Day 1, or ongoing adverse events from previous treatment with investigational drugs, regardless of the time period;
- •17. Within the 28-day screening period, documented red cell folate deficiency, as evidenced by red blood cell folate (not serum folate) or vitamin B12 deficiency.
研究者
相似试验
进行中（未招募）
1 期
To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid ArthritisMedDRA version: 18.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2012-004339-21-PLsanofi-aventis Recherche & Développement200
进行中（未招募）
不适用
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisEUCTR2009-015556-15-CZBiogen Idec Limited76
进行中（未招募）
不适用
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisEUCTR2009-015556-15-LVBiogen Idec Limited76
进行中（未招募）
1 期
A Multicenter, Randomized, Open-Label, Parallel-Group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS)The myelodysplastic syndromes (MDS) are a group of potentially acute myeloid leukemic disorders. The disorders of myeloid origin include acute myeloid leukemia (AML), MDS and myeloproliferative disorders such as chronic myeloid leukemia.MedDRA version: 6.1Level: PTClassification code 10028533EUCTR2004-001507-35-CZPharmion Corporation32
已完成
3 期
Study to assess Efficacy and Safety of Combination Tablet of Dapagliflozin, Sitagliptin and Metformin Hydrochloride Tablets in Comparison to Combination Tablet of Sitagliptin and Metformin Hydrochloride in Patients With Type 2 Diabetes MellitusCTRI/2022/04/041817Sun Pharma Laboratories Limited270